Finding the most effective treatment for your patients with metastatic castration-resistant prostate cancer (mCRPC) can be a challenge. The Oncotype DX AR-V7 Nucleus Detect test helps you quickly and confidently determine the next steps for treatment.
Confidently guide treatment decisions in mCRPC
Not all mCRPC patients respond to androgen receptor (AR)-targeted therapies, like abiraterone and enzalutamide.1 When AR-targeted therapy fails, acquired resistance could be the cause.1
Image shows a possible mCRPC treatment path
The only predictive and prognostic test for patients with mCRPC, the AR-V7 Nucleus Detect® test:
- Accurately identifies patients who may not benefit from AR-targeted therapies2,3
- Predicts improved overall survival with taxanes versus AR-targeted therapies2,3
- Provides easy-to-interpret results (a positive or negative result)
Why the AR-V7 Nucleus Detect Test for Your mCRPC Patients?
The Oncotype DX AR-V7 Nucleus Detect test is an assay that identifies patients who may not respond to androgen receptor (AR)-targeted therapy and should receive chemotherapy or other therapies instead.1-4